Newsfeeds - Spark Newswire

6 minute read

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

Today, 12:03 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)

ADTX

5 minute read

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical

By Shanthi Rexaline

Today, 12:03 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)

ABSI

3 minute read

FDA
News

CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C

By Benzinga Newsdesk

Today, 12:03 PM

CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today

CYTR

2 minute read

Earnings Scheduled For August 24, 2021

By Benzinga Insights

Today, 12:03 PM

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is likely to report earnings for its second quarter.

AAP

1 minute read

Investors React Positively To Data From Orphazyme’s Neurodegenerative Disease Candidate

By Vandana Singh

Today, 12:03 PM

Orphazyme A/S (NASDAQ:ORPH) announced that results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) had…

ORPH

2 minute read

News

Orphazyme Announces Publication of Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-pick Disease Type C in the Journal of Inherited Metabolic Disease; Trial Demonstrated a Statistically Significant and Clinically Meaningful Treatment Effect o…

By Charles Gross

Today, 12:03 PM

Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced that results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) have been published in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD). The online publication is available here.

ORPH

6 minute read

66 Biggest Movers From Yesterday

By Lisa Levin

Today, 12:03 PM

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share.

ABST

4 minute read

48 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 12:03 PM

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) gained 82% to $25.19. The company, last month, priced its IPO at $11 per share.

ABST

7 minute read

85 Biggest Movers From Yesterday

By Lisa Levin

Today, 12:03 PM

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.

ABVC

6 minute read

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO

By Shanthi Rexaline

Today, 12:03 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)

ACAD